Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Sponsor
Chinese Academy of Medical Sciences
Study ID
NCT03735082
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    apatinib 250mg,qd,d1-14,14day/cycle
  • Paclitaxel — DRUG
    paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
  • Carboplatin — DRUG
    carboplatin AUC=4,d1,14day/cycle;

Study Details

The purpose of this study is to assess the efficacy and safety of Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast patients

Key Dates

Start date
Nov 1, 2018
Status verified
Nov 2018
Primary completion
Jun 1, 2020
Completion
Jun 1, 2020

Study Design

Enrollment
29 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib+Paclitaxel+Carboplatin
    apatinib 250mg, d1-14,14day/cycle; Paclitaxel 175mg/m2,d1,14days/cycle; Carboplatin AUC=4,d1,14day/cycle

Primary Outcome Measure

pCR rate [ Time Frame: 3 months ]

Central Contacts

Related Studies